MYC and cancer: We have previously described a selective HDAC6 inhibitor, C1A, with good pharmacokinetics and in vivo potency in solid tumour xenografts.19 In this work, we evaluated the effect of C1A on  autophagy and cell death in cancer subtypes presumed to be susceptible to autophagy inhibition (including cells harbouring mutant KRAS, Myc protein, or cells that produce high levels of immunoglogulin and are dependent on efficient clearance of cytotoxic misfolded protein aggregates for survival).1,20,21